Director at Myriad Genetics (MYGN) receives 59,701 restricted stock units

Rhea-AI Filing Summary

Myriad Genetics director Daniel Skovronsky received an equity award of 59,701 shares of common stock in the form of restricted stock units. The grant was made at no cash cost to him and represents compensation rather than an open-market purchase.

Each restricted stock unit converts into one share of Myriad Genetics common stock and will vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following the grant. After this award, Skovronsky holds a total of 195,507 shares of common stock directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Skovronsky Daniel

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	59,701	$0.00	--

Holdings After Transaction: Common Stock — 195,507 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 59,701 shares Price per share for grant: $0.0000 per share Shares held after transaction: 195,507 shares +2 more

5 metrics

RSU grant size 59,701 shares Restricted stock units of common stock granted to director

Price per share for grant $0.0000 per share Equity award granted at no cash cost to recipient

Shares held after transaction 195,507 shares Total common stock directly owned by Daniel Skovronsky after award

Vesting condition – anniversary First anniversary of grant date One of the vesting triggers for the restricted stock units

Vesting condition – annual meeting Next annual meeting of stockholders Alternative vesting trigger for the restricted stock units

Key Terms

restricted stock units, 2026 Employee, Director and Consultant Equity Incentive Plan, annual meeting of stockholders

3 terms

restricted stock units financial

"Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2026 Employee, Director and Consultant Equity Incentive Plan financial

"granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended"

annual meeting of stockholders regulatory

"vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Skovronsky Daniel

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UTAH 84116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		A		59,701(1)	A	$0	195,507	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant.

Remarks:

	By: Justin Hunter For: Daniel Skovronsky	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Myriad Genetics (MYGN) report for Daniel Skovronsky?

Myriad Genetics reported that director Daniel Skovronsky received 59,701 restricted stock units as an equity award. These units represent compensation and not an open-market share purchase, and each unit corresponds to one share of the company’s common stock upon vesting.

How many Myriad Genetics shares did Daniel Skovronsky hold after this Form 4 transaction?

Following the equity award, Daniel Skovronsky held 195,507 shares of Myriad Genetics common stock directly. This total reflects the addition of 59,701 restricted stock units granted as compensation under the company’s 2026 Employee, Director and Consultant Equity Incentive Plan.

What are the vesting terms of Daniel Skovronsky’s 59,701 restricted stock units at Myriad Genetics?

The 59,701 restricted stock units vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders. Each vested unit entitles Daniel Skovronsky to receive one share of Myriad Genetics common stock, subject to the plan’s conditions.

Was cash paid for the 59,701 Myriad Genetics shares reported in this Form 4?

No cash was paid for these 59,701 shares, as the Form 4 lists a price per share of 0.0000. The award represents a grant of restricted stock units under an equity incentive plan, functioning as non-cash compensation for Daniel Skovronsky’s service.

Under which plan were Daniel Skovronsky’s restricted stock units in Myriad Genetics granted?

The restricted stock units were granted under Myriad Genetics’ 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. This plan provides equity-based awards to directors, employees, and consultants, aligning their compensation with the company’s common stock performance over time.